This page shows the latest Medicxi news and features for those working in and with pharma, biotech and healthcare.
to Medicxi, with European companies growing in stature and offering improved returns on investment for backers. ... to the US, Medicxi’s co-founder Francesco De Rubertis told the Financial Times.
The breadth of candidates in Sosei Heptares’ pipeline prompted the company to hive off some neurological programmes into two virtual companies – called Orexia and Inexia - with funding from Medicxi Ventures.
life sciences investor group Medicxi, the venture capital arm of Japanese drugmaker Taiho.
Gadeta was founded in 2015 by Professor Jürgen Kuball, Mark de Boer, Utrecht Holdings and venture fund Medicxi, its founding investor.
Two new investors, Medicxi and RA Capital Management, participated in the financing, which will fund the development of T-Guard into phase III registration trials, arranging commercial-scale production and marketing
Backed by Novartis and Alphabet's Verily unit, Medicxi Ventures has set up a $300m biotech fund that will back European growth-stage biotechs - that it says do not have access ... The European life sciences sector is recognised for its innovation, but
More from news
Approximately 1 fully matching, plus 6 partially matching documents found.
Richard Mason (pictured above) is a veteran of the UK biotech industry, including a spell as CEO of company XO1 set up by venture capital investors Index Ventures (now Medicxi) in
One key venture capital fund is London-based Medicxi, which raised 400m ($450m) from investors earlier this year for its third biopharma development fund. ... Medicxi III will be also supported by the investment firm’s scientific advisory board, which
More from intelligence
Approximately 0 fully matching, plus 2 partially matching documents found.
He joins the life science investment firm as a partner. London, UK-based life science investment group Medicxi has appointed former GSK chairman of pharmaceutical R&D, vaccines Dr Moncef Slaoui ... He said: “Having developed a strong relationship with
More from appointments
Approximately 1 fully matching, plus 0 partially matching documents found.
A team of strategic decision specialists with over 30+ years in the pharma space, we give you confidence through experience....